Data on the efficacy and safety of SG as a staged or primary procedure are just now being collected. A few short-term series with more than 100 patients have been conducted, but findings are insufficient to conclude that the approach offers greater pre-operative safety than any other WLS procedure.
However, collective retrospective data suggest that it is at least as safe as RYGB, with an overall complication rate of approximately 24% and a mortality rate of 0.37%. Evidence suggests that SG is as effective as RYGB at treating obesity and its comorbidities.
Like malabsorptive procedures, SG produces a marked and sustained reduction in ghrelin levels up to a year after the procedure; an outcome that may reduce desire for food.